Calcium Supplements and Cardiovascular Risk

Save

Dr. Nancy Lane answers questions about the intake of Calcium, Vitamin D and the cardiovascular risk of supplemental calcium.

Increased Comorbidities in Rheumatoid Arthritis

Save

A population based study from Taiwan examined the frequencies of comorbidities in a rheumatoid arthritis (RA) population.

Enthesitis-Related Arthritis in Children

Save

Enthesitis-related arthritis (ERA) is an emerging subset of juvenile idiopathic arthritis (JIA) recognized for its distinctive clinical characteristics.

NEJM: Adalimumab and MTX Effective in JIA Uveitis

Save

The NEJM has published the results of a randomized, placebo-controlled trial showing adalimumab and methotrexate is effective in reducing ocular flares in juvenile idiopathic arthritis with uveitis. 

FDA Approves Abaloparatide for High Risk Patients

Save

The FDA has approved injectable Tymlos (abaloparatide) for use in postmenopausal osteoporosis patients at high risk for fracture, as the drug has been shown to reduce the risk of vertebral and nonvertebral fractures in such patients.

Best to Rehab at Home Following Joint Replacement

Save

A New York Times article sheds light on recent evidence suggesting that those undergoing hip or knee replacement will do just as well with home therapy compared to inpatient rehabilitation following surgery.

Pregnancy Flares in RA and Spondylitis

Save

Despite the folklore, not all women with arthritis who become pregnant will improve or go into remission.  Recent studies have suggested that up to one-third of RA patients will flare during pregnancy.

Consensus on OP Drug Holidays

Save

Extending bisphosphonate treatment beyond 3–5 years does not confer additional benefit in low-risk populations. Treatment re-initiation (usually 1–3 years after bisphosphonate withdrawal) depends on risk factors, new fractures and bone mineral density. The evidence regarding denosumab discontinuation is limited but caution is advised, as there may be a “rebound effect” with regard to fractures.

FDA Approves Renflexis as Second Infliximab Biosimilar

Save

On the 21st of April, the FDA approved another infliximab biosimilar, called Renflexis (Infliximab-abda) following on the biologics license application of the South Korean manufacturer Samsung Bioepis Co. LTD.  In early developmental trials this agent was also called SB2.

The RheumNow Week in Review – 21 April 2017

Save

Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

Paradoxical Toxicities with TNF Inhibitors

Save

Something is curiously wrong when a drug induces the disease it is intended to treat. Yet this phenomenon has been described with all five FDA-approved TNF inhibitors.

FDA Delays Baricitinib Decision

Save

Eli Lilly and Company and Incyte Corporation announced today that the U.S. Food and Drug Administration (FDA) has delayed its' decision on baricitinib by issuing a complete response letter for baricitinib's New Drug Application. 

The RheumNow Week in Review – 14 April 2017

Save

Dr. Jack Cush reviews the past week's news, articles and advances from RheumNow.com.

Celecoxib Plus PPI Preferred in High Risk Patients

Save

When do the risks outweigh the benefits of NSAIDs use, especially in those with prior cardiovascular and gastrointestinal events? The CONCERN study has tested the effects of proton-pump inhibitor (PPI) in preventing GI bleeds when using NSAIDs and ASA.

Osteoporosis Screening Indicated Following Non-Vertebral Fractures

Save

The Archives of Osteoporosis have published the results of a cohort study supporting the use of osteoporosis (OP) screening in those sustaining a non-vertebral fracture in patients over age 50 years, independent of sex of level of trauma sustained.

Abatacept Use During Surgery

Save

The issue of medication management is a complicated one, especially in complex rheumatoid arthritis (RA) patients taking biologic or immunosuppressive drugs.

The RheumNow Week in Review – 31 March 2017

Save

Dr. Jack Cush reviews highlights from the news and Advances in Targeted Therapies meeting in Mandelieu, France:

Tweeting this week from Advances in Targeted Therapies #ATT2017 in Mandelieu, France.

TNF Inhibitor Induced Psoriasis

Save

Tumor necrosis factor-α inhibitors (TNFi) rarely have been reported to induce new-onset psoriasis.

Alcohol Use During Methotrexate Studied

Save

A recent RheumNow survey of 495 rheumatologists found that half of rheumatologists allow 1-3 alcoholic drinks per week and 6-7% has no alcohol restrictions while being treated with methotrexate (MTX).

ICER Report Claims RA Drugs are Not Cost Effective

Save

On Friday March 24, the nonprofit Institute for Clinical and Economic Review (ICER) presented its report on the cost and value of targeted immune modulators (TIMs) for rheumatoid arthritis (RA) in a meeting in Boston that included clinical experts, manufacturers, payers, and patients.